Apotex Strengthens Leadership Structure for Future Growth Apotex has announced key leadership changes, including a new CEO, to enhance its strategic direction and accelerate growth for the company.

Apotex Strengthens Leadership Structure for Future Growth #Canada #Toronto #CEO #Leadership_Changes #Apotex

Apotex Launches CLOBIVIS™, A New Ophthalmic Solution Approved by Health Canada Apotex Inc. secures Health Canada's approval for CLOBIVIS™, marking a significant addition to their ophthalmology offerings.

Apotex Launches CLOBIVIS™, A New Ophthalmic Solution Approved by Health Canada #Canada #Toronto #Apotex #Health_Canada #CLOBIVIS™

Grünenthal Partners with Apotex for Testosterone Therapy Nebido® in Canada Grünenthal has struck a deal with Apotex to license Nebido® for testosterone replacement in Canada, enhancing patient access and treatment options.

Grünenthal Partners with Apotex for Testosterone Therapy Nebido® in Canada #Canada #Toronto #Grünenthal #Apotex #Nebido

Apotex Secures Exclusive Canadian Rights for Testerone Therapy Nebido® from Grünenthal Apotex has obtained exclusive rights to market Nebido®, a testosterone replacement therapy, in Canada from Grünenthal. This partnership will enhance access to treatments for men's health.

Apotex Secures Exclusive Canadian Rights for Testerone Therapy Nebido® from Grünenthal #Canada #Toronto #Grünenthal #Apotex #Nebido

Apotex Celebrates Historic Health Canada Approval for LOQTORZI®, Groundbreaking Treatment for Nasopharyngeal Cancer Apotex Inc. proudly announces Health Canada has approved LOQTORZI®, the first immuno-therapy for recurrent nasopharyngeal cancer. This pivotal milestone brings new hope to patients.

Apotex Celebrates Historic Health Canada Approval for LOQTORZI®, Groundbreaking Treatment for Nasopharyngeal Cancer #Canada #Toronto #Cancer_Treatment #Apotex #LOQTORZI

Apotex Advances Women's Health with Canadian Rights to Linzagolix for Uterine Fibroids Apotex has secured exclusive rights to linzagolix in Canada, enhancing treatment options for women suffering from uterine fibroids, significantly impacting patient care.

Apotex Advances Women's Health with Canadian Rights to Linzagolix for Uterine Fibroids #Canada #Toronto #Women's_Health #Apotex #Linzagolix

Apotex Gains Health Canada Approval for Aflivu™, a Significant Step in Retinal Disease Treatment Apotex announces Health Canada's approval of Aflivu™, a biosimilar to Eylea®. This development offers a more affordable treatment for various retinal diseases.

Apotex Gains Health Canada Approval for Aflivu™, a Significant Step in Retinal Disease Treatment #Canada #Toronto #Apotex #Aflivu™ #Eylea®

Apotex Launches Nilotinib Capsules: First Generic Tasigna® in the U.S. Market Apotex Corp. has launched nilotinib capsules, the first generic version of Tasigna® in the U.S., enhancing access to critical leukemia treatment.

Apotex Launches Nilotinib Capsules: First Generic Tasigna® in the U.S. Market #United_States #Apotex #nilotinib #Tasigna #Weston,_Florida

Apotex's 2024 Sustainability Report Highlights Major Environmental Improvements The 2024 Sustainability Report from Apotex reveals significant strides in eco-friendly practices and social impact, showcasing the company's commitment to responsible business.

Apotex's 2024 Sustainability Report Highlights Major Environmental Improvements #Canada #Toronto #Environmental_Impact #Sustainability_Report #Apotex

Apotex Unveils IVRA™: A Revolutionary Melphalan Injection for Healthcare Apotex Corp. has launched IVRA™, the first ready-to-dilute liquid formulation of Melphalan injection, approved in the US, enhancing patient care.

Apotex Unveils IVRA™: A Revolutionary Melphalan Injection for Healthcare #USA #Weston #Apotex #IVRA #Melphalan

Apotex Expands Licensing Agreement for Clobetasol Propionate in Mexico Apotex Inc. has announced an exclusive licensing arrangement with Formosa Pharmaceuticals for clobetasol propionate in Mexico to treat post-surgical ocular conditions.

Apotex Expands Licensing Agreement for Clobetasol Propionate in Mexico #Mexico #Mexico_City #Formosa_Pharmaceuticals #Apotex #Clobetasol

Apotex and Grünenthal Collaborate for Exclusive Pain Management Rights in Canada Apotex has secured exclusive rights to Qutenza® from Grünenthal, enhancing options for neuropathic pain treatment in Canada. This partnership aims to improve patient care and expand drug availability.

Apotex and Grünenthal Collaborate for Exclusive Pain Management Rights in Canada #Canada #Toronto #Grünenthal #Apotex #Qutenza

Apotex Secures Exclusive Rights to Qutenza® for Canadian Market from Grünenthal Apotex has recently licensed exclusive Canadian rights to Qutenza®, a revolutionary pain patch from Grünenthal, enhancing options for neuropathic pain management.

Apotex Secures Exclusive Rights to Qutenza® for Canadian Market from Grünenthal #Canada #Toronto #Grünenthal #Apotex #Qutenza®

Apotex Supports Maternal Health Initiatives with $242,000 Grant to Broward Coalition Apotex Inc. has announced a significant $242,000 annual grant to support maternal health initiatives in Broward County. This funding aims to improve health equity in the community.

Apotex Supports Maternal Health Initiatives with $242,000 Grant to Broward Coalition #USA #Maternal_Health #Apotex #Broward_County #Lauderhill

Apotex Makes Strategic Acquisition of US Rights to PROVIGIL and NUVIGIL Apotex Inc. has successfully acquired the US rights to PROVIGIL and NUVIGIL, enhancing its portfolio in specialty healthcare and commitment to improving patient care.

Apotex Makes Strategic Acquisition of US Rights to PROVIGIL and NUVIGIL #Canada #Toronto #Provigil #Nuvigil #Apotex

Vanda Expands Efforts to Pull Two Hetlioz Copies From US Shelves Vanda Pharmaceuticals Inc. expanded its efforts to get Apotex Inc. and Teva Pharmaceuticals Industries Ltd.’s generic versions of its Hetlioz sleep-disorder drug pulled from US shelves, alleging in tw...

"Vanda Pharmaceuticals Inc. expanded its efforts to get Apotex Inc. and Teva Pharmaceuticals Industries Ltd.’s generic versions of its Hetlioz sleep-disorder drug pulled from US shelves..." Paywall, couldn't read the whole thing.
#Non24 #Hetlioz #Teva #Apotex
news.bloomberglaw.com/ip-law/vanda...

Dozens of states, including Kansas, reach settlements with pharmaceutical companies accused in price-fixing scheme Connecticut led 50 states and territories, including Kansas, in a lawsuit against the two companies for deliberately reducing competition and inflating prices in the market.

Heritage #Pharma ($10M) & #Apotex ($39.1M) settle allegations of "widespread, long-running conspiracies" to price-fix #generic drugs.
www.wibw.com/2024/11/26/d... #fraud #greed #BarrySherman
Maybe we should be more careful whom we celebrate as "a great leader in health care"?
/1